Metsera (NASDAQ:MTSR) Sees Large Volume Increase – Time to Buy?

Metsera Inc. (NASDAQ:MTSR) shares saw an uptick in trading volume on Thursday . 2,969,041 shares changed hands during mid-day trading, an increase of 90% from the previous session’s volume of 1,561,622 shares.The stock last traded at $70.45 and had previously closed at $70.75.

Analyst Ratings Changes

Several brokerages have recently issued reports on MTSR. Wells Fargo & Company lowered Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price target on the stock. in a research note on Tuesday, September 30th. Wall Street Zen upgraded Metsera from a “sell” rating to a “hold” rating in a research report on Wednesday, October 1st. Leerink Partners reissued a “market perform” rating and set a $57.00 target price (down previously from $77.00) on shares of Metsera in a research note on Wednesday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Metsera in a research note on Wednesday, September 3rd. Finally, Leerink Partnrs cut shares of Metsera from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Metsera has an average rating of “Hold” and a consensus target price of $55.75.

Metsera Trading Down 0.4%

The firm has a market capitalization of $7.43 billion and a price-to-earnings ratio of -11.16. The firm’s 50-day moving average is $53.47 and its 200 day moving average is $39.03.

Metsera (NASDAQ:MTSR) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.55).

Institutional Investors Weigh In On Metsera

A number of institutional investors have recently made changes to their positions in MTSR. Vanguard Group Inc. increased its stake in shares of Metsera by 290.6% in the third quarter. Vanguard Group Inc. now owns 5,824,993 shares of the company’s stock valued at $304,822,000 after buying an additional 4,333,514 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in Metsera in the first quarter valued at approximately $78,748,000. Wellington Management Group LLP acquired a new stake in Metsera during the 1st quarter valued at approximately $65,382,000. Alpha Wave Global LP bought a new position in Metsera during the 1st quarter worth approximately $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Metsera in the 1st quarter worth approximately $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.